1. Introduction

Biological Supply Chain Traceability Law refers to the legal and regulatory principles governing the identification, documentation, monitoring, and verification of biological materials as they move through a supply chain—from their original source to their final destination.

Biological materials include:

• Human blood, tissues, cells, organs, and biological specimens.
• Vaccines, medicines, biologics, and other biotechnology products.
• Genetically modified organisms (GMOs) and genetically engineered seeds.
• Animal products, livestock, and animal-derived biological materials.
• Microorganisms, laboratory samples, and infectious biological agents.
• Human genetic data, genomic samples, and associated research materials.
• Plant genetic resources and biological materials obtained from biodiversity.
• Laboratory-grown meat, synthetic biology products, and emerging biotechnology materials.

Traceability is important because biological materials may present risks that ordinary commercial products do not. A contaminated vaccine can endanger thousands of patients; an improperly documented human tissue sample can violate consent and privacy rights; and biological material obtained from an Indigenous community without appropriate authorization may raise questions of benefit-sharing, cultural rights, and control over genetic resources.

Biological supply chain traceability law therefore connects several branches of law:

1. Public health and pharmaceutical regulation.
2. Environmental and biodiversity law.
3. Human rights and constitutional law.
4. Consumer protection and product liability.
5. Data protection and genetic privacy.
6. Intellectual property and biotechnology law.
7. International trade and biosafety regulation.
8. Criminal law, evidence preservation, and regulatory enforcement.

Important legal distinction: There is no single universally applicable statute called the Biological Supply Chain Traceability Act. Instead, traceability obligations arise from different laws governing particular materials, industries, jurisdictions, and risks. The precise legal requirements depend on what is being traced, where it originates, and how it is used.

2. Meaning and Scope of Biological Traceability

Biological traceability is the ability to reconstruct the history, location, movement, handling, transformation, and distribution of a biological material throughout its lifecycle.

For example, the traceability of a vaccine may require records identifying:

• The manufacturer and production facility.
• The relevant production batch or lot.
• The raw materials used in manufacturing.
• Quality-control and testing results.
• Storage temperatures and transportation conditions.
• Wholesalers, distributors, hospitals, and pharmacies receiving the product.
• The healthcare facilities where the vaccine was administered, where applicable and legally justified.
• Any adverse event reports, recalls, or corrective measures.

A traceability system should make it possible to determine which products are affected when contamination or another safety problem is discovered.

2.1 The principal stages

These requirements are not identical for every biological product. A commercial medicine, a human embryo, a research specimen, and a genetically modified crop may be subject to substantially different legal frameworks.

3. Objectives of Biological Supply Chain Traceability Law

3.1 Protection of public health

The first objective is to prevent unsafe biological products from reaching patients and the public.

Traceability enables authorities and manufacturers to identify affected batches, determine the distribution of defective products, investigate adverse events, and implement recalls.

3.2 Prevention of contamination and biological hazards

Biological materials can be affected by microbial contamination, incorrect storage, cross-contamination, mishandling, or unauthorized modification.

Traceability helps investigators determine where a problem originated and which parties may have contributed to it.

3.3 Prevention of fraud and counterfeiting

A traceable supply chain can help detect counterfeit medicines, falsified biological products, unauthorized substitutions, and misleading claims concerning a product's origin.

However, traceability alone does not prove authenticity. Effective verification may also require validated testing, secure records, inspection, and independent audits.

3.4 Protection of human dignity and privacy

Biological samples and genomic information may reveal sensitive information about an individual and their relatives.

A legally adequate system must distinguish between tracking the physical sample and identifying the person from whom it originated. These functions should not automatically be combined.

For example, a laboratory may need to trace a specimen to a particular research project without providing every distributor with the donor's name or complete medical history.

3.5 Biodiversity conservation and equitable benefit-sharing

Biological materials collected from plants, animals, microorganisms, and other genetic resources may be subject to access permits, prior informed consent, mutually agreed terms, or benefit-sharing obligations.

Traceability can help establish whether biological resources were acquired and transferred lawfully and whether applicable obligations continue to be observed.

3.6 Regulatory accountability

Traceability creates an evidentiary record through which regulators, courts, auditors, and affected individuals may investigate wrongdoing.

Nevertheless, the existence of records does not automatically establish compliance. Records must be accurate, complete, reliable, and capable of independent verification.

4. Legal Framework in India

India does not have one comprehensive statute covering the traceability of every type of biological material. Instead, its legal framework is distributed across pharmaceutical regulation, environmental law, biodiversity protection, food safety, data protection, and human-tissue governance.

4.1 Drugs and Cosmetics Act, 1940, and Drugs Rules, 1945

The Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945, form a central part of India's framework for regulating medicines and biological products.

The regulatory framework addresses the manufacture, import, distribution, and sale of drugs, including relevant biological products. The Central Drugs Standard Control Organization (CDSCO) performs important regulatory functions concerning licensing, product approvals, inspections, and pharmacovigilance. DGHS Health Ministry

Relevance to traceability

Manufacturers and other regulated entities must comply with the recordkeeping, quality-control, licensing, and other requirements applicable to their particular products and activities.

For example, where a vaccine batch is found to be contaminated, relevant production and distribution records can help establish:

1. The batch in which the problem originated.
2. The raw materials and manufacturing processes involved.
3. The locations to which the batch was distributed.
4. Whether other batches may be affected.
5. Whether withdrawal, recall, investigation, or other regulatory action is required.

The exact obligations depend on the product category and applicable rules. It would be incorrect to assume that every biological material is subject to identical pharmaceutical traceability requirements.

Legal significance: Failure to maintain required records or comply with applicable licensing and quality standards may lead to regulatory enforcement. Civil or criminal liability, however, depends on the particular statutory provision, the conduct involved, and the evidence available.

Official regulatory reference: CDSCO biological products and regulatory functions.

4.2 Medical Devices Rules, 2017

Medical devices used in the diagnosis, prevention, monitoring, or treatment of disease may be subject to the Medical Devices Rules, 2017.

The Indian regulatory framework expressly addresses identification and traceability in the applicable medical-device quality-management requirements. The Drugs and Cosmetics Rules material published by India Code also contains provisions on documented traceability procedures, product identification, and records for relevant medical devices. CDSCO

Traceability is especially important for:

• Implantable medical devices.
• Devices incorporating biological materials.
• In-vitro diagnostic products.
• Products that must be tracked for safety notices or recalls.
• Devices for which the manufacturer's records must identify the recipient or distribution chain.

Example: If a batch of an implantable device fails a safety test, appropriate records may help identify the affected devices and determine which hospitals or patients may require follow-up.

4.3 Environment (Protection) Act, 1986, and GMO regulation

The Environment (Protection) Act, 1986 provides the legislative basis for important environmental controls, including rules governing hazardous microorganisms and genetically engineered organisms.

The Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells, 1989, establish a regulatory framework for specified activities involving genetically engineered organisms and hazardous microorganisms.

Depending on the organism and activity, regulatory oversight can involve institutions such as:

• The Genetic Engineering Appraisal Committee (GEAC).
• The Review Committee on Genetic Manipulation (RCGM).
• Institutional Biosafety Committees.
• Other designated regulatory and monitoring authorities.

Traceability implications

The relevant records may need to establish the identity of the organism, its source, the approved activity, the conditions of use, and the movement or disposal of regulated materials.

For genetically modified seeds or crops, traceability may also help distinguish authorized planting material from unauthorized material and investigate unintended environmental release.

However, the precise recordkeeping and reporting obligations must be determined from the applicable authorization, rules, guidelines, and product-specific conditions.

4.4 Biological Diversity Act, 2002

The Biological Diversity Act, 2002, as amended, provides a framework for regulating access to biological resources and associated traditional knowledge and for sharing benefits arising from their utilization.

The relevant authorities and procedures depend on the person seeking access, the biological resource, the proposed activity, applicable exemptions, and the provisions in force.

How traceability supports compliance

A traceable record of biological resources may establish:

• Where the material was collected.
• Who collected or supplied it.
• Whether the collection was authorized.
• Which permits or approvals were obtained.
• Whether associated traditional knowledge was involved.
• How the material was transferred to researchers or commercial entities.
• Whether applicable benefit-sharing conditions were fulfilled.

For instance, a company developing a commercial biotechnology product from a biological resource obtained in India may need to investigate the applicable access, approval, and benefit-sharing requirements before commercialization.

Traceability is an evidentiary and compliance tool; it does not, by itself, determine whether a particular transaction requires approval or benefit-sharing.

4.5 Food Safety and Standards Act, 2006

The Food Safety and Standards Act, 2006 establishes India's framework for food safety and the regulation of food businesses.

Biological supply chain traceability is relevant to food ingredients, animal-derived products, seeds, food-producing animals, and biotechnology-related food products, subject to the applicable legislation and regulations.

For example, if a foodborne illness is linked to a particular ingredient, source and distribution records may help identify the affected products, determine their destination, and support withdrawal or recall.

Food safety traceability also serves a consumer-protection function by helping prevent misleading representations about the identity, origin, or composition of products.

4.6 Digital Personal Data Protection Act, 2023

Biological supply chains increasingly rely on digital records containing donor details, patient information, genetic identifiers, and laboratory data.

The Digital Personal Data Protection Act, 2023 is relevant where the processing of digital personal data falls within its scope and the applicable provisions are in force.

Genetic and health-related information may be particularly sensitive in practical terms because it can reveal information about an individual and, in some circumstances, their relatives.

A traceability system should therefore consider:

• Whether personal information is actually necessary.
• Whether the purpose of processing is lawful.
• Who may access identifiable records.
• How long records must be retained.
• Whether the data may be transferred to another organization.
• How unauthorized access or disclosure will be prevented.

The legal analysis must distinguish between physical biological samples, digitized information about those samples, and information that can identify a person. Their treatment under different legal regimes may differ.

4.7 Human biological materials and consent

Human blood, tissues, cells, embryos, and other biological specimens raise issues beyond ordinary commercial traceability.

Depending on the activity, relevant Indian frameworks may include clinical-trial regulations, biomedical and health research ethics requirements, assisted reproductive technology legislation, transplantation legislation, and applicable institutional standards.

A legally adequate traceability system should preserve evidence of consent, collection purpose, authorized uses, transfers, and disposal where these are required.

Key principle: Traceability cannot cure an absence of legally required consent. A complete record of an unauthorized collection remains evidence of an unauthorized collection.

5. International Legal Framework

Biological supply chains frequently cross national borders. International standards and treaties therefore influence domestic regulation, although their precise legal effect depends on the relevant treaty, national implementation, and the type of material involved.

5.1 Nagoya Protocol on Access and Benefit-sharing

The Nagoya Protocol supplements the Convention on Biological Diversity by establishing an international framework for access to genetic resources and fair and equitable benefit-sharing.

Article 6 addresses access to genetic resources, including prior informed consent where required under the applicable framework. Article 5 addresses benefit-sharing, while other provisions address compliance and related institutional arrangements. Convention on Biological Diversity

The Protocol is important when biological resources are collected in one country and transferred to researchers, laboratories, or commercial entities in another.

Example

Suppose a pharmaceutical company obtains a microorganism from a country whose applicable access-and-benefit-sharing rules require prior informed consent and mutually agreed terms.

A traceability system may document:

1. The country and source of the microorganism.
2. The permit or other authorization.
3. The applicable mutually agreed terms.
4. Transfers to laboratories or commercial partners.
5. Changes in the material's intended use.
6. Relevant benefit-sharing obligations.

The Protocol does not create an identical permit requirement for every biological material in every country. Its operation depends on the applicable treaty obligations and domestic legal framework.

Official reference: Nagoya Protocol text.

5.2 Cartagena Protocol on Biosafety

The Cartagena Protocol on Biosafety addresses the safe handling, transport, and use of living modified organisms resulting from modern biotechnology, particularly in relation to biodiversity and potential risks to human health.

Its provisions concerning documentation, handling, transport, packaging, and identification are relevant to international movements of specified living modified organisms.

Traceability can help authorities identify the organism, understand the purpose of a shipment, verify applicable documentation, and respond to accidental release or other incidents.

However, the Protocol's documentation requirements differ according to the category and intended use of the organism. It should not be treated as a universal tracking law for every genetically modified product.

5.3 World Trade Organization agreements

Two WTO agreements can be relevant to biological supply chains:

• The Agreement on the Application of Sanitary and Phytosanitary Measures (SPS Agreement).
• The Agreement on Technical Barriers to Trade (TBT Agreement).

The SPS Agreement is relevant to measures protecting human, animal, or plant life or health from specified risks, including risks associated with pests, diseases, and contaminants. The TBT Agreement concerns technical regulations, standards, and conformity-assessment procedures within its scope.

Traceability and documentation requirements may form part of a country's regulatory system for biological products, food, and agricultural goods.

Such measures must be assessed against the applicable WTO obligations; their legality cannot be determined merely by describing them as traceability requirements.

5.4 European Union food traceability law

Article 18 of Regulation (EC) No. 178/2002 establishes traceability requirements for food, feed, food-producing animals, and substances intended to be incorporated into food or feed.

It requires relevant operators to identify their suppliers and the business recipients of their products, subject to the regulation's terms and applicable sector-specific requirements. Legislation.gov.uk

The familiar operational principle is often described as "one step back, one step forward."

This means that a business should generally be able to identify its immediate supplier and the businesses to which it supplied the relevant product. More detailed requirements may apply in particular sectors.

This framework is useful as a comparative model for designing biological supply chains, but it should not be mistaken for a universal EU rule covering all human tissues, medicines, or biological materials.

6. Important Case Laws Relating to Biological Supply Chain Traceability

There is no single body of case law devoted exclusively to biological supply chain traceability. Its legal principles are developed through decisions involving biotechnology, product safety, informed consent, privacy, environmental regulation, and regulatory accountability.

The following cases are particularly useful for understanding the legal principles that can govern traceability disputes.

Case 1: Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019)

Citation: (2019) 3 SCC 381
Court: Supreme Court of India
Subject: Genetically modified seeds, biotechnology patents, and scientific evidence.

The dispute concerned Monsanto's patented biotechnology used to introduce insect-resistant traits into cotton plants and the licensing of that technology to seed companies.

The litigation raised questions about the relationship between patented genetic engineering processes, genetically modified plant varieties, and the legal treatment of biotechnology inventions.

The Supreme Court held that the technically complex questions concerning patentability and the relevant biological and biotechnological processes required proper adjudication and expert evidence. It set aside the High Court Division Bench's summary disposition and restored the Single Judge's interim order while remanding the suit for disposal according to law. The Court did not finally resolve every substantive question of patentability. Sci API

Relevance to biological traceability

Although this was not a direct traceability case, it illustrates why records identifying genetically modified materials, their characteristics, their authorized use, and their movement through seed supply chains can be important evidence.

A traceability system for genetically modified seeds may help establish:

• The identity of the genetic trait involved.
• The source of the seed material.
• Whether the relevant variety was authorized for commercial release.
• Which companies handled or distributed the material.
• Whether the disputed material was used under the relevant licensing arrangements.

Legal principle: In technically complex biotechnology disputes, reliable documentary evidence and appropriate expert examination are essential. Traceability records may support such evidence but do not independently determine patent ownership, infringement, or regulatory approval.

Case 2: K.S. Puttaswamy v. Union of India (2017)

Citation: (2017) 10 SCC 1
Court: Supreme Court of India
Subject: Constitutional privacy and informational autonomy.

In this landmark judgment, a nine-judge bench of the Supreme Court recognized privacy as a fundamental right protected by the Constitution.

The judgment addressed the relationship between privacy, dignity, personal liberty, and informational autonomy.

Relevance to biological traceability

Modern biological traceability systems may collect or process information concerning:

• Blood donors and tissue donors.
• Patients receiving biological medicines.
• Individuals participating in genomic research.
• People whose biological samples are stored in laboratories.
• Individuals whose genetic information is linked to research databases.

The constitutional principles recognized in Puttaswamy are relevant when state action or applicable privacy protections are implicated by the collection, retention, or disclosure of such information.

For example, a government database intended to trace biological samples may create privacy risks if it collects unnecessary identifying information or permits unrestricted access to genetic records.

A legally sound system should therefore distinguish between the legitimate need to trace a specimen and the separate question of whether the identity of the donor must be disclosed.

Legal principle: Biological traceability should be designed consistently with applicable privacy protections, necessity, proportionality, and safeguards against unjustified interference with individual autonomy.

The case does not establish a universal prohibition on identifiable biological records; the legality of a particular system depends on its purpose, legal basis, safeguards, and circumstances.

Case 3: Samira Kohli v. Dr. Prabha Manchanda (2008)

Citation: (2008) 2 SCC 1
Court: Supreme Court of India
Subject: Medical consent and patient autonomy.

The case concerned medical procedures performed without the patient's consent extending to the additional procedure undertaken.

The Supreme Court explained the importance of informed consent and the limits of the consent given by a patient for medical treatment.

Relevance to biological supply chains

Biological traceability may document the collection, storage, transfer, and use of human biological material.

For example, a laboratory may maintain complete records showing that a tissue sample was transferred to a research institution. Those records do not, by themselves, establish that the donor authorized the particular research use.

The distinction is crucial where biological materials are transferred between hospitals, laboratories, universities, biotechnology companies, or research organizations.

A compliance system should record the applicable consent or authorization, the permitted purpose, and any restrictions on further use where required by law or ethics standards.

Legal principle: Accurate documentation of a biological material's movement cannot substitute for legally required informed consent.

The case concerns medical consent rather than a general statutory regime for biological sample tracking. Its relevance is therefore based on the underlying principle of patient autonomy.

Case 4: Common Cause v. Union of India (2018)

Citation: (2018) 5 SCC 1
Court: Supreme Court of India
Subject: Dignity, autonomy, and end-of-life medical decision-making.

The Supreme Court addressed the legality of passive euthanasia and advance directives within a framework protecting dignity and individual autonomy.

The judgment is not a supply chain traceability decision. Its relevance is more limited and concerns the importance of legally significant medical records and respect for individual autonomy in healthcare.

Application

Where biological materials are collected or used in healthcare, records may need to preserve evidence of the relevant authorization, treatment decision, or applicable legal restriction.

The broader lesson is that healthcare documentation should support the rights of the individual rather than operate merely as an administrative tracking mechanism.

Legal principle: Medical records and authorization procedures should be consistent with applicable legal requirements concerning dignity, autonomy, and patient rights.

Case 5: Vellore Citizens' Welfare Forum v. Union of India (1996)

Citation: (1996) 5 SCC 647
Court: Supreme Court of India
Subject: Environmental protection and the precautionary principle.

The case concerned environmental pollution caused by tanneries in Tamil Nadu.

The Supreme Court recognized the importance of the precautionary principle and the polluter-pays principle within Indian environmental law.

Relevance to biological supply chains

Biological supply chains can create environmental risks through the release of hazardous microorganisms, improper disposal of biological waste, or the escape of regulated genetically engineered organisms.

Traceability can help identify the source of a biological release, determine which operators handled the material, and establish the movement of potentially hazardous substances.

Suppose a biotechnology facility releases a regulated organism into the environment. Appropriate records may help investigators identify the source, reconstruct relevant transfers, and assess which corrective measures are necessary.

The precautionary principle may support preventive action where there is a scientifically credible risk of serious environmental harm, subject to the applicable legal framework.

Legal principle: Environmental accountability may require both preventive safeguards and the ability to identify the sources of pollution or environmental risk.

The judgment does not itself impose a universal biological traceability requirement. Rather, it supplies environmental principles relevant to the design and enforcement of traceability systems.

Case 6: Indian Council for Enviro-Legal Action v. Union of India (1996)

Citation: (1996) 3 SCC 212
Court: Supreme Court of India
Subject: Environmental liability and remediation costs.

The case concerned serious environmental pollution and the responsibility of industrial operators for the resulting harm.

The Supreme Court applied environmental liability principles, including the polluter-pays principle.

Relevance to biological traceability

Where a biological manufacturing or processing facility causes environmental harm, records concerning the origin, handling, movement, and disposal of biological materials may help establish responsibility.

For example, investigators may need to determine whether contaminated material originated at a manufacturing site, was transferred by a distributor, or was improperly disposed of by a downstream operator.

Traceability evidence may contribute to the factual assessment of responsibility and remediation costs.

Legal principle: Traceability can support the identification of responsible operators, but liability still depends on the applicable legal duties, causation, evidence, and the relevant statutory or common-law principles.

Case 7: Novartis AG v. Union of India (2013)

Citation: (2013) 6 SCC 1
Court: Supreme Court of India
Subject: Pharmaceutical innovation and patentability.

The case concerned the patentability of a modified form of an existing pharmaceutical substance under Section 3(d) of the Patents Act, 1970.

The Supreme Court considered the statutory requirements governing patent protection and the evidence concerning the claimed pharmaceutical innovation.

Relevance to biological supply chains

Pharmaceutical traceability may involve records of raw materials, manufacturing processes, product batches, quality testing, and distribution.

In biotechnology disputes, these records may also help establish which product was manufactured, which process was used, and whether the relevant product is the one covered by a particular regulatory authorization or patent claim.

However, Novartis primarily concerns patentability. It should not be cited as if it directly establishes a statutory duty to maintain biological supply chain records.

Legal principle: Pharmaceutical regulation and intellectual property law involve distinct legal inquiries. Traceability records may be relevant evidence, but they do not independently establish patentability or regulatory compliance.

Case 8: M.C. Mehta v. Union of India — Oleum Gas Leak Case (1987)

Citation: (1987) 1 SCC 395
Court: Supreme Court of India
Subject: Hazardous industrial activities and absolute liability.

Following the escape of oleum gas from an industrial facility in Delhi, the Supreme Court developed the doctrine of absolute liability for enterprises engaged in hazardous or inherently dangerous activities.

Relevance to biological supply chains

A facility handling hazardous biological agents may create risks that require strict operational controls, secure storage, appropriate transportation procedures, and reliable incident records.

The case supplies a broader principle for considering the responsibilities of enterprises engaged in hazardous activities. Whether the doctrine applies to a particular biological incident depends on the nature of the activity and the applicable law.

Traceability records may help establish how a hazardous material moved through the supply chain and where failures occurred.

Legal principle: Enterprises engaged in activities that create serious hazards may face substantial liability when their operations cause harm. Traceability can assist in establishing the relevant facts but does not itself determine liability.

7. Comparative Summary of the Case Laws

Academic caution: These judgments do not collectively create a standalone doctrine of biological supply chain traceability. They provide legal principles that may apply to particular traceability disputes. A case directly concerning the relevant product or statutory recordkeeping requirement should be preferred when available.

8. Legal Duties of Different Supply Chain Participants

Biological traceability requires a clear allocation of responsibility among the entities involved.

8.1 Manufacturers

Manufacturers may be required to maintain records concerning:

• Raw materials and their sources.
• Manufacturing and processing activities.
• Quality-control results.
• Batch identification.
• Storage and release decisions.
• Distribution records.
• Complaints, adverse events, and recalls.

The precise duties depend on the relevant product category and regulatory framework.

A manufacturer should not release a regulated product merely because its records appear complete. The product must also satisfy the applicable quality, safety, and authorization requirements.

8.2 Laboratories and research institutions

Laboratories handling biological specimens should use appropriate identification systems and document relevant transfers, processing steps, storage conditions, and authorized uses.

Research institutions may also need to preserve evidence of ethics approval, consent, access permits, or biosafety authorization.

Where a specimen is transferred to another institution, the transfer documentation should identify the material and establish the applicable conditions for its further use.

8.3 Distributors and transport operators

Depending on the applicable rules, distributors and transport operators may need to preserve information about:

• The consignor and recipient.
• The identity and quantity of the material.
• Relevant shipment or batch identifiers.
• Storage and transportation conditions.
• Delivery and transfer dates.
• Temperature excursions or other incidents.

For temperature-sensitive biological products, records of storage conditions can be critical to determining whether the product remained suitable for use.

8.4 Hospitals and healthcare providers

Hospitals and healthcare providers may need to maintain relevant records linking biological products to their use in patient care.

For example, where a vaccine is subject to a safety recall, appropriate records can help identify which doses were administered and which patients may require follow-up.

Access to patient-identifying records must nevertheless comply with applicable privacy and confidentiality requirements.

8.5 Government regulators

Regulatory authorities may inspect records, investigate noncompliance, impose lawful restrictions, and coordinate recalls or other protective measures within their statutory powers.

Effective oversight requires more than collecting documents. Authorities must be able to assess whether the records are reliable, whether they cover the relevant transactions, and whether the regulated entity has complied with the applicable legal requirements.

9. Chain of Custody and Biological Evidence

An important aspect of biological traceability is the chain of custody.

Chain of custody is the documented history of the collection, possession, transfer, handling, and preservation of evidence or material.

It is particularly important when biological materials are used in criminal investigations, civil litigation, regulatory proceedings, or scientific testing.

9.1 Essential elements

A sound chain-of-custody procedure ordinarily records:

1. The identity or unique reference number of the sample.
2. The date, time, and circumstances of collection.
3. The identity and authorization of the person collecting it.
4. The sealing, packaging, and labeling procedure.
5. Each transfer between persons or institutions.
6. Storage conditions and relevant deviations.
7. The identity of each person accessing the sample.
8. Testing, analysis, and any consumption or alteration of the material.
9. The final disposition of the sample.

The exact legal requirements vary according to the material and proceeding.

9.2 Why chain of custody matters

Suppose a laboratory analyzes a biological sample and obtains a result suggesting contamination.

The result may be challenged if the opposing party demonstrates that:

• The sample was incorrectly identified.
• Its seal was broken without explanation.
• It was stored under unsuitable conditions.
• The records do not account for a period in which it was transferred.
• The analytical method was unreliable.
• The result cannot be linked to the original material.

A gap in the chain of custody does not necessarily make the evidence inadmissible in every jurisdiction. Its effect depends on the applicable evidence rules, the nature of the gap, and whether the reliability of the evidence can otherwise be established.

9.3 Indian evidentiary law

In India, biological evidence may be relevant under the Bharatiya Sakshya Adhiniyam, 2023, which governs evidence subject to its scope and applicable exceptions.

Where electronic traceability records are produced, the applicable provisions concerning electronic and digital records must also be considered.

A party relying on a laboratory database, electronic transfer log, or digital audit trail must establish the evidentiary foundation required by the law applicable to the proceeding.

Important distinction: A traceability database is not automatically conclusive evidence. Its reliability, authenticity, completeness, and connection to the disputed material may all require examination.

10. Digital Traceability, Blockchain, and Artificial Intelligence

Modern biological supply chains increasingly use digital technologies to record transactions and detect anomalies.

10.1 Blockchain-based traceability

A blockchain system can record transactions across a distributed ledger.

Potential applications include tracking the transfer of pharmaceutical batches, documenting authorized transfers of genetic resources, and maintaining records of biological materials held by multiple organizations.

However, blockchain presents an important limitation: an immutable record can preserve inaccurate information just as effectively as accurate information.

If a biological sample is mislabeled before its details are entered into the ledger, the blockchain does not automatically correct the original mistake.

A sound system therefore requires reliable verification at the point of data entry.

10.2 Artificial intelligence

AI systems may analyze supply chain records to identify:

• Unusual shipment patterns.
• Potentially counterfeit products.
• Missing or inconsistent records.
• Suspicious temperature excursions.
• Unexpected transfers of controlled biological materials.
• Patterns that may indicate contamination or diversion.

These systems can support human decision-making, but automated risk scores should not be treated as conclusive proof of misconduct.

Where an AI-generated alert results in a regulatory penalty, licence suspension, or other adverse decision, the responsible authority must comply with the applicable legal requirements for evidence, reasons, procedural fairness, and review.

10.3 Data protection and cybersecurity

Digital traceability systems may create new risks, including unauthorized disclosure of genetic information, tampering with records, identity theft, and unauthorized access to controlled biological materials.

Appropriate safeguards may include:

• Role-based access controls.
• Encryption.
• Authentication and access logs.
• Secure backups.
• Record-integrity checks.
• Documented correction procedures.
• Incident reporting and response mechanisms.
• Periodic independent audits.

The safeguards should be proportionate to the sensitivity of the information and the risks posed by the material.

11. Major Legal Challenges

11.1 Fragmented regulation

Biological materials may fall under pharmaceutical, environmental, biodiversity, food safety, medical research, or privacy laws.

A single supply chain may therefore involve several regulatory authorities.

The challenge is to coordinate these requirements without creating contradictory reporting obligations or leaving gaps in oversight.

11.2 Confidentiality versus traceability

Traceability may require access to records identifying the source or recipient of a material, while privacy and commercial confidentiality may restrict disclosure.

A practical solution is to provide authorized regulators with the information necessary for their statutory functions while limiting unnecessary disclosure to other parties.

11.3 Cross-border transfers

A biological material may be collected in one country, processed in another, and commercialized in a third.

Different jurisdictions may impose different rules on permits, consent, data transfers, storage, and benefit-sharing.

Organizations should identify the applicable laws at each stage rather than assuming that compliance in the country of origin resolves every subsequent legal issue.

11.4 Errors in traceability records

Incorrect labeling, duplicate identifiers, incomplete logs, and inaccurate digital entries can undermine the entire system.

The law should encourage timely correction, preserve audit history, and distinguish accidental errors from deliberate falsification.

11.5 Allocation of liability

When harm occurs, several parties may have contributed to the problem.

For example, a manufacturer may have produced a defective batch, a transporter may have breached storage requirements, and a distributor may have failed to preserve required records.

Liability should be assessed according to the applicable duties, evidence, causation, and statutory framework. The mere presence of a company in the supply chain does not automatically make it liable for every subsequent harm.

11.6 Commercial secrecy and public accountability

Companies may claim that manufacturing information, genetic sequences, or sourcing arrangements constitute confidential business information.

Nevertheless, confidentiality should not automatically prevent regulators from obtaining information they are legally entitled to access.

The challenge is to protect legitimate confidentiality interests while maintaining effective safety oversight and enforcing applicable disclosure obligations.

12. A Model Framework for Biological Supply Chain Traceability

A comprehensive traceability framework should incorporate the following components.

These are proposed elements of a model framework, not a statement that every element is expressly mandated for every biological product under Indian law.

12.1 Risk-based traceability

The degree of traceability should reflect the nature of the material and the risks involved.

For example:

• A vaccine may require batch-level traceability and relevant cold-chain documentation.
• A transplantable organ may require specialized donor-recipient and clinical documentation.
• A regulated genetically modified organism may require identification and documentation associated with its authorized handling and movement.
• A research specimen may require records of collection, consent, permitted use, and transfer.
• A biological food ingredient may be subject to supplier and recipient identification requirements under applicable food law.

A risk-based approach can make traceability more effective while avoiding unnecessary collection of personal information.

13. Remedies and Enforcement for Traceability Violations

The consequences of a traceability failure depend on the applicable law and the circumstances of the violation.

13.1 Regulatory remedies

Depending on the governing statute and the relevant authority's powers, possible measures include:

• Inspection and investigation.
• Directions to correct recordkeeping deficiencies.
• Suspension or cancellation of an authorization where legally justified.
• Product withdrawal or recall.
• Restrictions on distribution.
• Penalties for specified statutory violations.

13.2 Civil liability

Civil claims may arise where a traceability failure contributes to personal injury, property damage, breach of contract, or another legally recognized harm.

A claimant generally must establish the elements of the relevant cause of action. Missing records may be important evidence, but their absence does not automatically establish every element of liability.

13.3 Criminal liability

Criminal consequences may arise where the conduct satisfies the elements of a criminal offence—for example, a relevant offence involving adulteration, prohibited distribution, deliberate falsification, or another specifically prohibited act.

Criminal liability must be based on the applicable offence and the required standard of proof.

13.4 Constitutional and judicial remedies

Where state action violates a fundamental right or exceeds statutory authority, judicial review or constitutional remedies may be available.

The principles in K.S. Puttaswamy, Vellore Citizens' Welfare Forum, and M.C. Mehta may be relevant depending on whether the dispute concerns privacy, environmental harm, or hazardous activity.

Their application is context-dependent; none creates a general constitutional right to trace every biological material in every circumstance.

14. Critical Analysis: Toward a Biological Traceability Doctrine

A broader legal doctrine of biological supply chain traceability can be developed from existing regulatory and judicial principles. This is an analytical framework rather than the name of an independently enacted statute or a universally recognized doctrine.

The framework can be organized around five principles.

Principle 1: Provenance accountability

Regulated biological materials should be identifiable to the extent necessary to establish their lawful source and authorized movement.

This principle is particularly important for medicines, controlled biological agents, regulated GMOs, and genetic resources subject to access requirements.

Principle 2: Evidentiary integrity

Traceability records should be accurate, verifiable, and preserved in a form suitable for the relevant regulatory or judicial purpose.

This principle connects supply chain management with chain-of-custody requirements and the evidentiary standards applied in litigation.

Principle 3: Proportionality and privacy

The need to trace a biological material should not automatically justify unrestricted collection or disclosure of personal genetic information.

The system should collect and disclose only the information justified by the applicable legal purpose.

Principle 4: Environmental and public health responsibility

Traceability should support the timely identification of contamination, unauthorized releases, defective products, and other risks.

The precautionary principle and environmental liability doctrines may inform the response where the relevant legal conditions are satisfied.

Principle 5: Accountable digital governance

Digital records, automated risk assessments, and AI-based monitoring should remain subject to appropriate human oversight, record-integrity safeguards, and legally available review.

A technology should improve accountability rather than make responsibility impossible to identify.

Taken together, these principles suggest that traceability is not merely a technical exercise. It is a method of linking biological materials to the legal responsibilities of the people and organizations that collect, process, transfer, distribute, or use them.

15. Conclusion

Biological Supply Chain Traceability Law is an interdisciplinary area of legal regulation concerned with establishing the identity, provenance, movement, handling, and authorized use of biological materials.

In India, the relevant legal framework is distributed across the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, medical-device regulations, environmental and GMO rules, biodiversity legislation, food safety law, privacy legislation, and other sector-specific regimes.

The principal judicial authorities contribute different parts of the legal foundation:

• Monsanto Technology LLC v. Nuziveedu Seeds Ltd. highlights the importance of technical evidence in biotechnology disputes.
• K.S. Puttaswamy v. Union of India provides the constitutional foundation for protecting informational privacy.
• Samira Kohli v. Dr. Prabha Manchanda emphasizes the importance of informed consent in medical treatment.
• Vellore Citizens' Welfare Forum v. Union of India supports environmental protection and precautionary approaches.
• Indian Council for Enviro-Legal Action v. Union of India addresses environmental responsibility and remediation.
• M.C. Mehta v. Union of India establishes an important liability principle for hazardous activities.

These authorities are relevant by analogy or within their particular legal fields; they should not be represented as judgments directly establishing a universal biological traceability obligation.

The central legal proposition is that traceability must connect reliable records with lawful sourcing, appropriate authorization, product safety, privacy protection, and identifiable accountability. A supply chain may be fully documented yet still be unlawful if the material was obtained without required consent or authorization. Conversely, a traceability system that protects confidentiality while preserving reliable evidence can strengthen public health, environmental protection, scientific integrity, and the rule of law.

For academic research, the most important next step is to identify the particular biological material and applicable statutory regime. That makes it possible to distinguish binding traceability obligations from broader principles derived from case law and regulatory policy.